Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.

NASDAQ:SUPN

Overview | Financials
Company Name Supernus Pharmaceuticals, Inc.
Symbol SUPN
Currency USD
Price 40
Market Cap 2,208,772,000
Dividend Yield 0%
52-week-range 25.53 - 40.24
Industry Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Mr. Jack A. Khattar
Website https://www.supernus.com

An error occurred while fetching data.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis

Related Stocks

Dynavax Technologies Corporation logo

Dynavax Technologies Corporation

DVAX

13 USD

Vaxcyte, Inc. logo

Vaxcyte, Inc.

PCVX

86.515 USD

Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc.

XENE

39.98 USD

Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc.

TVTX

21.1 USD

Krystal Biotech, Inc. logo

Krystal Biotech, Inc.

KRYS

161.3 USD

ImmunityBio, Inc. logo

ImmunityBio, Inc.

IBRX

3.19 USD

Establishment Labs Holdings Inc. logo

Establishment Labs Holdings Inc.

ESTA

30.725 USD

Addus HomeCare Corporation logo

Addus HomeCare Corporation

ADUS

123.02 USD

Ligand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated

LGND

117.26 USD

Financials

Numbers are in millions USD

Numbers are in millions USD